Transcriptomic Analysis Identifies the Effect of Beta-Blocking Agents on a Molecular Pathway of Contraction in the Heart and Predicts Response to Therapy

Bettina Heidecker, Michelle M. Kittleson, Edward K. Kasper, Ilan S. Wittstein, Hunter C. Champion, Stuart D. Russell, Kenneth L. Baughman, Joshua Hare

Research output: Contribution to journalReview article

2 Scopus citations

Abstract

Over the last decades, beta-blockers have been a key component of heart failure therapy. However, currently there is no method to identify patients who will benefit from beta-blocking therapy versus those who will be unresponsive or worsen. Furthermore, there is an unmet need to better understand molecular mechanisms through which heart failure therapies, such as beta-blockers, improve cardiac function, in order to design novel targeted therapies. Solving these issues is an important step towards personalized medicine. Here, we present a comprehensive transcriptomic analysis of molecular pathways that are affected by beta-blocking agents and a transcriptomic biomarker to predict therapy response.

Original languageEnglish (US)
Pages (from-to)107-121
Number of pages15
JournalJACC: Basic to Translational Science
Volume1
Issue number3
DOIs
StatePublished - Apr 1 2016

Keywords

  • beta-blocking agents
  • biomarker
  • gene expression
  • heart failure
  • transcriptomics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Transcriptomic Analysis Identifies the Effect of Beta-Blocking Agents on a Molecular Pathway of Contraction in the Heart and Predicts Response to Therapy'. Together they form a unique fingerprint.

  • Cite this